Dianthus Therapeutics Banner


Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Lonnie Moulder

Chairman of the Board, Dianthus Therapeutics

Prior to establishing Tellus BioVentures, a lifesciences investment fund, Mr. Moulder co-founded TESARO and served as Chief Executive Officer and Director until its acquisition by GlaxoSmithKline. He previously served as President and Chief Executive Officer of Abraxis BioScience. Prior to Abraxis, he served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and Chief Executive Officer. This followed him serving as a member of the founding management team of a venture-stage biotech company. Mr. Moulder began his career as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.

Mr. Moulder is a Temple University Trustee and a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. He serves on the Board of Directors for Zai Lab, Helsinn Group and Trevena, and for the Tellus BioVentures portfolio companies: Aegle Therapeutics, Interius BioTherapeutics, Navrogen, Praeventix, TamuroBio, Vittoria and Zenas BioPharma (as Executive Chairman). Mr. Moulder received a Pharmacy degree from Temple University and an M.B.A from The University of Chicago Booth School of Business.

Chairman of the Board